BIIB : Summary for Biogen Inc. - Yahoo Finance

U.S. Markets open in 6 hrs 34 mins

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
286.90-2.04 (-0.71%)
At close: 4:00PM EST
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close288.94
Bid287.10 x 900
Ask287.98 x 100
Day's Range286.22 - 289.91
52 Week Range223.02 - 333.65
Avg. Volume1,861,081
Market Cap61.96B
PE Ratio (TTM)16.95
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals11 hours ago

    ​Top pharma lobbyist casts Biogen as the anti-Shkreli during drug price Q&A

    The head of the pharmaceutical industry’s biggest Washington lobby group visited Boston on Tuesday as part of a public relations campaign aimed at countering criticism of high drug prices — and singled out Cambridge-based Biogen for praise. During a question-and-answer session with reporters Tuesday, Stephen Ubl, the head of the Pharmaceutical Research and Manufacturers of America, spoke out against what he called a handful of “bad actors” — companies that purchase off-patent medicines that lack generic competition and then significantly raise the price. As an example, he pointed to Biogen’s (BIIB) Spinraza, which in December became the first drug approved to treat spinal muscular atrophy, a leading genetic cause of death in infants.

  • Investopedia2 days ago

    Celgene MS Drug Reports Positive Phase 3 Data

    Celgene’s multiple sclerosis drug ozanimod beat rival Avonex in a Phase 3 study.

  • 3 Top Drug Stocks That Can Be Purchased on the Cheap This Winter
    Motley Fool2 days ago

    3 Top Drug Stocks That Can Be Purchased on the Cheap This Winter

    Healthcare bargains abound for patient long-term investors.